Over 80% of the patients with prostate cancer (PCa) develop bone metastasis, which seriously affects the patients' quality of life and remains a major cause of morbidity. Radium-223 (Ra-223), a newly approved agent targeting bone metastasis of PCa, can improve the quality of life and prolong the overall survival of the PCa patients with bone metastasis. This article presents an overview of the clinical trials recently published on the management of bone metastasis of PCa with Ra-223.
骨是前列腺癌最常见的远处转移部位，超过 80%的前列腺癌患者发生骨转移。晚期骨转移严重影响患者的生存质量，同时也是导致其死亡的重要因素。镭- 223(Ra-223)是最近批准上市用于治疗骨转移性前列腺癌的新药，具有既能改善患者生活质量，又能延长患者总体生存期的优势。本文将对近年来Ra-223治疗前列腺癌 骨转移临床研究进展作一综述。.
Keywords: bone metastasis; prostate cancer; radium-223; treatment.